-
1
-
-
0027280249
-
LDL stimulates mesangial fibronectin production and chemoattractant expression
-
Rovin BH, Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43: 218-225, 1993
-
(1993)
Kidney Int
, vol.43
, pp. 218-225
-
-
Rovin, B.H.1
Tan, L.C.2
-
2
-
-
27744446645
-
Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/ AKT-signaling pathway
-
Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G: Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/ AKT-signaling pathway. J Am Soc Nephrol 16: 1936-1947, 2005
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 1936-1947
-
-
Bussolati, B.1
Deregibus, M.C.2
Fonsato, V.3
Doublier, S.4
Spatola, T.5
Procida, S.6
Di Carlo, F.7
Camussi, G.8
-
3
-
-
0035137324
-
Transcription factor-kB (NF-kB) and renal disease
-
Guijarro C, Egido J: Transcription factor-kB (NF-kB) and renal disease. Kidney Int 59: 415-424, 2001
-
(2001)
Kidney Int
, vol.59
, pp. 415-424
-
-
Guijarro, C.1
Egido, J.2
-
4
-
-
11844270511
-
Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases
-
Kuldo JM, Ogawara KI, Werner N, Asgeirsdottir SA, Kamps JA, Kok RJ, Molema G: Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Curr Vasc Pharmacol 3: 11-39, 2005
-
(2005)
Curr Vasc Pharmacol
, vol.3
, pp. 11-39
-
-
Kuldo, J.M.1
Ogawara, K.I.2
Werner, N.3
Asgeirsdottir, S.A.4
Kamps, J.A.5
Kok, R.J.6
Molema, G.7
-
5
-
-
0033050559
-
Effect of simvastatin on proliferative nephritis and cell-cycle protein expression
-
Yoshimura A, Nemoto T, Sugenoya Y, Inui K, Watanabe S, Inoue Y, Sharif S, Yokota N, Uda S, Morita H, Ideura T: Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int Suppl 71: S84-S87, 1999
-
(1999)
Kidney Int Suppl
, vol.71
-
-
Yoshimura, A.1
Nemoto, T.2
Sugenoya, Y.3
Inui, K.4
Watanabe, S.5
Inoue, Y.6
Sharif, S.7
Yokota, N.8
Uda, S.9
Morita, H.10
Ideura, T.11
-
6
-
-
26444478235
-
Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction
-
Vieira JM Jr. Mantovani E, Rodrigues LT, Delle H, Noronha IL, Fujihara CK, Zatz R: Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 20: 1582-1591, 2005
-
(2005)
Nephrol Dial Transplant
, vol.20
, pp. 1582-1591
-
-
Vieira Jr., J.M.1
Mantovani, E.2
Rodrigues, L.T.3
Delle, H.4
Noronha, I.L.5
Fujihara, C.K.6
Zatz, R.7
-
7
-
-
0031883707
-
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats
-
Park Y-S, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31: 190-194, 1998
-
(1998)
Am J Kidney Dis
, vol.31
, pp. 190-194
-
-
Park, Y.-S.1
Guijarro, C.2
Kim, Y.3
Massy, Z.A.4
Kasiske, B.L.5
Keane, W.F.6
O'Donnell, M.P.7
-
8
-
-
0042376168
-
-
Mason JC: Statins and their role in vascular protection. Clin Sci (Lond) 105: 251-266, 2003 9 Crisby M: Modulation of the inflammatory process by statins. Drugs Today (Barc) 39: 137-143, 2003
-
Mason JC: Statins and their role in vascular protection. Clin Sci (Lond) 105: 251-266, 2003 9 Crisby M: Modulation of the inflammatory process by statins. Drugs Today (Barc) 39: 137-143, 2003
-
-
-
-
9
-
-
0141857806
-
Noncholesterol-lowering effects of statins
-
Pierre-Paul D, Gahtan V: Noncholesterol-lowering effects of statins. Vasc Endovascular Surg 37: 301-313, 2003
-
(2003)
Vasc Endovascular Surg
, vol.37
, pp. 301-313
-
-
Pierre-Paul, D.1
Gahtan, V.2
-
10
-
-
0034685031
-
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin
-
Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP: Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun 267: 536-540, 2000
-
(2000)
Biochem Biophys Res Commun
, vol.267
, pp. 536-540
-
-
Massy, Z.A.1
Kim, Y.2
Guijarro, C.3
Kasiske, B.L.4
Keane, W.F.5
O'Donnell, M.P.6
-
11
-
-
0029147229
-
Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin
-
Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF: Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 48: 363-371, 1995
-
(1995)
Kidney Int
, vol.48
, pp. 363-371
-
-
Kim, S.Y.1
Guijarro, C.2
O'Donnell, M.P.3
Kasiske, B.L.4
Kim, Y.5
Keane, W.F.6
-
12
-
-
0036150077
-
Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose
-
Chen HC, Guh JY, Shin SJ, Lai YH: Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 160: 141-146, 2002
-
(2002)
Atherosclerosis
, vol.160
, pp. 141-146
-
-
Chen, H.C.1
Guh, J.Y.2
Shin, S.J.3
Lai, Y.H.4
-
13
-
-
0030003977
-
Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells
-
Guijarro C, Kim Y, Schoonover CM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Kashtan CE: Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant 11: 990-996, 1996
-
(1996)
Nephrol Dial Transplant
, vol.11
, pp. 990-996
-
-
Guijarro, C.1
Kim, Y.2
Schoonover, C.M.3
Massy, Z.A.4
O'Donnell, M.P.5
Kasiske, B.L.6
Keane, W.F.7
Kashtan, C.E.8
-
14
-
-
0037233913
-
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells
-
Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23: 58-63, 2003
-
(2003)
Arterioscler Thromb Vasc Biol
, vol.23
, pp. 58-63
-
-
Dichtl, W.1
Dulak, J.2
Frick, M.3
Alber, H.F.4
Schwarzacher, S.P.5
Ares, M.P.6
Nilsson, J.7
Pachinger, O.8
Weidinger, F.9
-
15
-
-
0036445650
-
Modulation of inflammatory mediators and PPARgamma and NfkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro
-
Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S: Modulation of inflammatory mediators and PPARgamma and NfkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45: 147-154, 2002
-
(2002)
Pharmacol Res
, vol.45
, pp. 147-154
-
-
Zelvyte, I.1
Dominaitiene, R.2
Crisby, M.3
Janciauskiene, S.4
-
16
-
-
0030820468
-
Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway
-
Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 52: 1016-1027, 1997
-
(1997)
Kidney Int
, vol.52
, pp. 1016-1027
-
-
Vrtovsnik, F.1
Couette, S.2
Prie, D.3
Lallemand, D.4
Friedlander, G.5
-
17
-
-
3042647296
-
HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: A potential mechanism of statin-mediated vasculoprotection
-
Vamvakopoulos JE, Green C: HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: A potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord 3: 6, 2003
-
(2003)
BMC Cardiovasc Disord
, vol.3
, pp. 6
-
-
Vamvakopoulos, J.E.1
Green, C.2
-
18
-
-
0035723275
-
HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism
-
Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, Numano F: HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 21: 1165-1171, 2001
-
(2001)
Arterioscler Thromb Vasc Biol
, vol.21
, pp. 1165-1171
-
-
Yoshida, M.1
Sawada, T.2
Ishii, H.3
Gerszten, R.E.4
Rosenzweig, A.5
Gimbrone Jr, M.A.6
Yasukochi, Y.7
Numano, F.8
-
20
-
-
0034844264
-
Atorvastatin improves endothelial function in renal-transplant recipients
-
Asberg A, Hartmann A, Fjeldsa E, Holdaas H: Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 16: 1920-1924, 2001
-
(2001)
Nephrol Dial Transplant
, vol.16
, pp. 1920-1924
-
-
Asberg, A.1
Hartmann, A.2
Fjeldsa, E.3
Holdaas, H.4
-
21
-
-
0032584177
-
Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
-
Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97: 1129-1135, 1998
-
(1998)
Circulation
, vol.97
, pp. 1129-1135
-
-
Laufs, U.1
La Fata, V.2
Plutzky, J.3
Liao, J.K.4
-
22
-
-
0346736491
-
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
-
Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719, 1998
-
(1998)
J Clin Invest
, vol.101
, pp. 2711-2719
-
-
Hernandez-Perera, O.1
Perez-Sala, D.2
Navarro-Antolin, J.3
Sanchez-Pascuala, R.4
Hernandez, G.5
Diaz, C.6
Lamas, S.7
-
23
-
-
46449134065
-
-
Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 58: 1420-1430, 2000 25 Zhou M-S, Jaimes EA, Raij L: Atorvastatin prevents end-organ injury in salt-sensitive hypertension: Role of eNOS and oxidant stress. Hypertension 44: 186-190, 2004
-
Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 58: 1420-1430, 2000 25 Zhou M-S, Jaimes EA, Raij L: Atorvastatin prevents end-organ injury in salt-sensitive hypertension: Role of eNOS and oxidant stress. Hypertension 44: 186-190, 2004
-
-
-
-
24
-
-
27144432809
-
Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD
-
Preston E, Ellis MR, Kulinskaya E, Davies AH, Brown EA: Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. Am J Kidney Dis 46: 856-862, 2005
-
(2005)
Am J Kidney Dis
, vol.46
, pp. 856-862
-
-
Preston, E.1
Ellis, M.R.2
Kulinskaya, E.3
Davies, A.H.4
Brown, E.A.5
-
25
-
-
0036162113
-
Cellular anti-oxidant effects of atorvastatin in vitro and in vivo
-
Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G: Cellular anti-oxidant effects of atorvastatin in vitro and in vivo. Aterioscler Thromb Vasc Biol 22: 300-305, 2002
-
(2002)
Aterioscler Thromb Vasc Biol
, vol.22
, pp. 300-305
-
-
Wassmann, S.1
Laufs, U.2
Muller, K.3
Konkol, C.4
Ahlbory, K.5
Baumer, A.T.6
Linz, W.7
Bohm, M.8
Nickenig, G.9
-
26
-
-
0035186999
-
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
-
Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108: 1429-1437, 2001
-
(2001)
J Clin Invest
, vol.108
, pp. 1429-1437
-
-
Takemoto, M.1
Node, K.2
Nakagami, H.3
Liao, Y.4
Grimm, M.5
Takemoto, Y.6
Kitakaze, M.7
Liao, J.K.8
-
27
-
-
0041342004
-
Cholesterol and the risk of renal dysfunction in apparently healthy men
-
Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084-2091, 2003
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 2084-2091
-
-
Schaeffner, E.S.1
Kurth, T.2
Curhan, G.C.3
Glynn, R.J.4
Rexrode, K.M.5
Baigent, C.6
Buring, J.E.7
Gaziano, J.M.8
-
28
-
-
0029166463
-
Effects of hypertension and dyslipidemia on the decline in renal function
-
Manttari M, Tiula E, Alikoski T, Manninen V: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26: 670-675, 1995
-
(1995)
Hypertension
, vol.26
, pp. 670-675
-
-
Manttari, M.1
Tiula, E.2
Alikoski, T.3
Manninen, V.4
-
29
-
-
0027462467
-
Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases
-
Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, Kodama T, Suzuki H, Maki S: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 43: 918-927, 1993
-
(1993)
Kidney Int
, vol.43
, pp. 918-927
-
-
Takemura, T.1
Yoshioka, K.2
Aya, N.3
Murakami, K.4
Matumoto, A.5
Itakura, H.6
Kodama, T.7
Suzuki, H.8
Maki, S.9
-
30
-
-
1342344698
-
Cellular lipid metabolism and the role of lipids in progressive renal disease
-
Abrass CK: Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24: 46-53, 2004
-
(2004)
Am J Nephrol
, vol.24
, pp. 46-53
-
-
Abrass, C.K.1
-
31
-
-
0035166933
-
-
Fried LF, Orchard TJ, Kasiske BL; for the Lipids and Renal Disease Progression Meta-Analysis Study Group: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260-269, 2001
-
Fried LF, Orchard TJ, Kasiske BL; for the Lipids and Renal Disease Progression Meta-Analysis Study Group: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260-269, 2001
-
-
-
-
32
-
-
85190678243
-
-
Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC; for the Cholesterol and Recurrent Events (CARE) Trial Investigators: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613, 2003
-
Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC; for the Cholesterol and Recurrent Events (CARE) Trial Investigators: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613, 2003
-
-
-
-
33
-
-
33646701223
-
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate
-
Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM: Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 97: 1602-1606, 2006
-
(2006)
Am J Cardiol
, vol.97
, pp. 1602-1606
-
-
Vidt, D.G.1
Harris, S.2
McTaggart, F.3
Ditmarsch, M.4
Sager, P.T.5
Sorof, J.M.6
-
34
-
-
27144534466
-
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease
-
Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF: Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 96: 1290-1292, 2005
-
(2005)
Am J Cardiol
, vol.96
, pp. 1290-1292
-
-
Verma, A.1
Ranganna, K.M.2
Reddy, R.S.3
Verma, M.4
Gordon, N.F.5
-
35
-
-
0036271883
-
Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients
-
Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39: 1213-1217, 2002
-
(2002)
Am J Kidney Dis
, vol.39
, pp. 1213-1217
-
-
Chang, J.W.1
Yang, W.S.2
Min, W.K.3
Lee, S.K.4
Park, J.S.5
Kim, S.B.6
-
36
-
-
0037373832
-
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease
-
Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
-
(2003)
Am J Kidney Dis
, vol.41
, pp. 565-570
-
-
Bianchi, S.1
Bigazzi, R.2
Caiazza, A.3
Campese, V.M.4
-
37
-
-
1542298565
-
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
-
Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57: 728-734, 2004
-
(2004)
J Clin Pathol
, vol.57
, pp. 728-734
-
-
Athyros, V.G.1
Mikhailidis, D.P.2
Papageorgiou, A.A.3
Symeonidis, A.N.4
Pehlivanidis, A.N.5
Bouloukos, V.I.6
Elisaf, M.7
-
38
-
-
1842829905
-
Rosuvastatin-induced arrest in progression of renal disease
-
Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102: 52-60, 2004
-
(2004)
Cardiology
, vol.102
, pp. 52-60
-
-
Vidt, D.G.1
Cressman, M.D.2
Harris, S.3
Pears, J.S.4
Hutchinson, H.G.5
-
39
-
-
0033673164
-
Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients
-
Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30: 980-987, 2000
-
(2000)
Eur J Clin Invest
, vol.30
, pp. 980-987
-
-
Tonolo, G.1
Melis, M.G.2
Formato, M.3
Angius, M.F.4
Carboni, A.5
Brizzi, P.6
Ciccarese, M.7
Cherchi, G.M.8
Maioli, M.9
-
40
-
-
38449119409
-
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study
-
James S, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zukerman A, Wenger NK. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2: 1131-1139, 2007
-
(2007)
Clin J Am Soc Nephrol
, vol.2
, pp. 1131-1139
-
-
James, S.1
Kastelein, J.J.P.2
Bittner, V.3
Deedwania, P.4
Breazna, A.5
Dobson, S.6
Wilson, D.J.7
Zukerman, A.8
Wenger, N.K.9
|